Literature DB >> 25606391

Interstitial 12p deletion involving more than 40 genes in a patient with postnatal microcephaly, psychomotor delay, optic nerve atrophy, and facial dysmorphism.

Anne Hoppe1, Jan Heinemeyer2, Eva Klopocki3, Luitgard M Graul-Neumann4, Birgit Spors5, Petra Bittigau2, Angela M Kaindl6.   

Abstract

Interstitial deletions of chromosome 12p are rare, and the phenotype spectrum is therefore still unknown. The thirteen patients reported so far suffer from developmental delay, optic nerve hypoplasia, micropenis, hypoplastic hair and skin, oligodontia, brachydactyly, and arterial hypertension. We report a de novo 12p12.2-p11.22 deletion of 9.2 Mb detected by array CGH analysis in a boy with global developmental delay, muscular hypotonia, postnatal microcephaly, facial dysmorphism including small ears, epicanthus, broad nasal bridge and hypoplastic nostrils. In addition, the patient had optic nerve atrophy, inverted nipples, micropenis, and a hemangioma. The deleted region encompasses more than 40 reference genes. We compare phenotype and deletion extent of our index patient to that of previous reports and thereby contribute to the understanding of interstitial 12p deletion phenotypes. Knowledge of the pattern of this deletion phenotype will help clinicians to diagnose this abnormality in their patients and to counsel the parents accordingly. Further descriptions may be able to contribute to the clarification.

Entities:  

Keywords:  Array CGH; Mental retardation; Microcephaly

Year:  2014        PMID: 25606391      PMCID: PMC4287802          DOI: 10.1016/j.mgene.2013.10.014

Source DB:  PubMed          Journal:  Meta Gene        ISSN: 2214-5400


Introduction

Deletions of the short arm of chromosome 12 are rare with only thirteen patients reported since the first description of an infant carrying the deletion 12p11p13 in 1975 (Bahring et al., 1997, Boilly-Dartigalongue et al., 1985, Fryns et al., 1990, Glaser et al., 2003, Lu et al., 2009, Macdonald et al., 2010, Magenis et al., 1981, Magnelli and Therman, 1975, Malpuech G et al., 1975, Nagai et al., 1995, Orye and Craen, 1975, Soysal et al., 2011, Stumm et al., 2007, Tenconi et al., 1975). A number of common features of patients with interstitial 12p deletions have emerged including global delay, cardiac anomalies (AVSD, VSD, ASD II), microcephaly, and optic nerve atrophy (Table 1). Still, the spectrum of the clinical phenotype remains unknown. Here, we describe a boy with a de novo interstitial deletion of chromosome 12. We characterized the extent of the deletion by array CGH and compared the phenotypic characteristics of the patient with those of previously published case studies.
Table 1

Comparison of phenotype between index patient and previously reported patients with interstitial 12p deletions. Abbreviations: m, male; f, female; y, year; mo, month; ADT, asphyxiating thoracic dystrophy.

Chromosome 12 segmentAgeSexIntellectual disabilityMotor delayCraniofacial dysmorphismMicrocephalyAtrophy of optic nerveDental anomaliesGenital hypo-plasiaSkeletal anomaliesDigital anomaliesCardio-vascular anomaliesArterial Hyper-tensionOtherReference
p11p132 mom+++++Tenconi et al. (1975)
p11p12.23 ym+++++Malpuech G et al. (1975)
p11p12.117 yf++++++++Boilly-Dartigalongue et al. (1985)
p11.1p12.112 yf++++++Soysal et al., 2011
p11.21p13.2Fetusf+++Cystic pelvic kidneyStumm et al. (2007)
p11.2p13.17.5 mof++++++Turner-like stigmataFryns et al. (1990)
p11.2p12.25 ym+++++ATDNagai et al. (1995)
p11.21p12.26 ym++Bahring et al. (1997)
p11.21p12.213 yf++++++Lu et al. (2009)
p11.22p11.2335 yf+Short statureDecipher 251557
p12.2p11.228 mom+++++++Short stature, hemangiomaOur case
p1213 mom+++++++Orye and Craen (1975)
p126.5 ym+++++Orye and Craen (1975)
p12.1p12.37m++++++Hearing/visual impairmentGlaser et al. (2003)
p12.1p12.311 ym++++Achalasia, apraxiaDecipher 139
p12.14 ym++Decipher 253839
p12.328 mom++++Magenis et al. (1981)
14914956351153Total (n = 17)

Material and methods

Karyotype

For chromosome analysis peripheral blood lymphocytes from the index patient, his brother, and his parents were karyotyped using standard protocols for cultivation and GTG banding at a level of 550 bands in accordance with the International System for Human Cytogenetic Nomenclature (ISCN) (Mitelman, 1995).

Array CGH analysis

We obtained blood samples from the index patient and his parents after written informed consent. Genomic DNA was isolated from peripheral blood lymphocytes according to standard procedures. Patient and female reference DNA (Promega, Mannheim, Germany) were labeled with Cy3 and Cy5 using the Genomic DNA Enzymatic Labeling Kit (Agilent, Santa Clara, CA) according to the manufacturer's protocol. The mixture was hybridized on a 180 K oligonucleotide array (Agilent, Santa Clara, CA) for 16 h in a hybridization oven. Image data were analyzed using Feature Extraction 9.5.3.1 and CGH Analytics 3.4.40 software (Agilent Technologies, Santa Clara, CA) with the following analysis settings: aberration algorithm ADM-2; threshold: 6.0; window size: 0.2 Mb; filter: 5 probes, log2ratio = 0.29. Genome coordinates are shown according to human genome build GRCh37(hg18).

Results

Phenotype

The boy is the second child of non-consanguineous and healthy parents of German descent (Fig. 1A). His mother reported two previous miscarriages and unilateral ear fistulas of two maternal half siblings. The index patient was born at term following an uneventful pregnancy without complications: birth weight 3390 g (40th centile; − 0.22 SD), length 50 cm (35th centile; 0 SD), occipitofrontal head circumference (OFC) 34 cm (15th centile; − 0.79 SD). He was first presented at 4 weeks-of-age for cyanotic spells, an eye movement disorder of intermittent exotropia and discrete anisocoria. At that time, a small persistent ductus arteriosus was diagnosed. At an age of eight months, he presented at our hospital because of a respiratory syncytial virus (RSV) bronchiolitis and an anal herpex simplex virus (HSV) 1 infection. On clinical investigation, he had significant psychomotor delay. Griffith testing revealed a developmental age of 10.5 months at the chronological age of 23.5 months (developmental quotient < 45%). Facial dysmorphism was noted i.e. small ears, epicanthus, broad nasal bridge, and hypoplastic nostrils (Fig. 1B, Supplemental Fig. 1). In addition, the patient showed a dystrophic growth at the age of 16 months: height 75.5 cm (0.5 cm < 3rd centile, − 1.48 SD), weight 9.78 kg (10th centile, − 1.40 SD), a postnatal (secondary) microcephaly (OFC 44.4 cm (1 cm < 3rd centile, − 2.31 SD)) (Fig. 1C), inverted nipples, a micropenis, a hemangioma on his lower extremities (Fig. 1B) and trunk hypotonia. Results of routine laboratory tests, metabolic screening, electroencephalogram (EEG) and echocardiogram were normal. No seizures were reported. The patient had a normal bone age shown by X-ray without signs of brachydactyly type E and normotensive blood pressure values. Abdominal ultrasound revealed mild splenomegaly. VEP and cranial MRI showed evidence of bilateral optic atrophy (Fig. 1D). Radiation-induced chromosome fragility was increased significantly at 1.0 Gy, although not as high as in patients with ataxia telangiectatica or Nijmegen breakage syndrome.
Fig. 1

Clinical and radiological phenotype of patient with 12p12.2–p11.22 deletion. (A) Pedigree; the patient's mother and brother showed a karyotype with a balanced Robertsonian translocation between chromosome 13 and 15 shown in gray shadings; (B) phenotype; (C) head circumference development illustrating postnatal microcephaly; (D) axial T1 cerebral MRI at the age of 8 months demonstrates bilateral optic nerve atrophy shown by a difference in the diameter of the intraorbital compared to the prechiasmal optic nerve (arrow) which is not present in an age-matched control.

Karyotype and array CGH

Conventional karyotyping indicated an interstitial deletion on the short arm of chromosome 12 [46,XY,del 12p11.2p12.?2]. To determine the size and the breakpoints more precisely we performed array CGH analysis using a high resolution oligonucleotide array. This analysis detected a 9.17 Mb deletion on chromosome 12p and thereby confirmed the previous results from karyotyping [arr[hg18] 12p12.2p11.22 (20,842,661-30,015,311)x1]. This region contains more than 40 known genes (Table 2) and extends from position 20.48 Mb to 30.01 Mb (Fig. 2). The patient's mother and brother showed a karyotype with a balanced Robertsonian translocation between chromosome 13 and 15.
Table 2

List of genes within deletion 12p12.2–p11.22.

GeneProteinOMIMFunction
SLCO1B3Solute carrier organic anion transporter family, member 1B3*605495Hepatic uptake
SLCO1A2Member 1A2*147940
SLCO1B1Member 1B1*604843
RECQLRECQ protein like*600537DNA repair helicase
ABCC9ATP-binding cassette, subfamily C, member 9*601439ATP-sensitive potassium channel in heart and skeletal muscle
IAPPIslet amyloid polypeptide*147940Role in pancreatic islet function, may be a factor in the etiology of the insulin resistance in type II diabetes mellitus
KCNJ8Potassium channel, inwardly-rectifying, subfamily J, member 8*600935ATP-sensitive potassium channel in coronary artery smooth muscle and endothelial cells
PYROXD1Pyridine nucleotide-disulphide oxidoreductase domain 1Role in human male germ cell tumor differentiation
GOLT1BGolgi transport 1B*615078Influences aspartate aminotransferase activity
GYS2Glycogen synthase 2*138571Catalyzes rate-limiting step in glycogen synthesis
LDHBLactate dehydrogenase B*150100Enzymatic activator of glycolysis, catalyzes interconversion of lactate and pyruvate
CMASCytidine 5-prime-monophosphatade N-acetylneuraminic acid synthetase*603316Activation of sialic acids, the terminal residues of cell surface glycoproteins and glycolipids
ST8SIA1Alpha N-acetyl-neuraminide alpha 2-8-sialyltransferase 1*601123Ganglioside synthase, catalyzes GD3 ganglioside formation
ETNK1Ethanolamine kinase 1*609858Catalyzes first step of phosphatidyl-ethanolamine synthesis pathway
SOX5SRY-Box 5*604975Role in chondrogenesis, oligodendrocyte differentiation and migration
BCAT1Branched-chain aminotransferase 1*113520Expressed early in embryogenesis, during organogenesis localized in neural tube, somites, and mesonephric tubules
LRMPLymphoid-restricted membrane protein*602003Expressed in a developmentally regulated manner in lymphoid tissues
KRASKirsten rat sarcoma viral oncogene*190070Role in tissue signaling, including proliferation, differentiation, and senescence, mutated genes are oncogenes
CASC1Cancer susceptibility candidate 1Candidate tumor suppressor gene implicated in lung tumorigenesis
RASSF8Ras association (RalGDS/AF-6) domain family (N-terminal) member 8*608231Role in maintaining adherens junction function in epithelial cells and has a role in epithelial cell migration, lung tumor suppressor gene candidate
BHLHE41Basic helix-loop-helix family, member E41*606200Transcriptional, regulator of molecular clock, defects are associated with a short sleep phenotype
SSPNSarcospan*601599Links subsarcolemmal cytoskeleton and extracellular matrix of muscle cells
ITPR2Inositol 1,4,5-trisphosphate receptor, type 2*600144Role in intracellular calcium response
FGFR1OP2Fibroblast growth factor receptor 1 oncogene partner 2*608858May regulate cell motility and stimulate wound closure
TM7SF3Transmembrane 7 superfamily member 3*605181Cell surface protein family, includes receptors for a variety of ligands
MED21Mediator complex subunit 21*603800Multiprotein coactivator member required by DNA-binding transcription factors for activation of polymerase II-transcribed genes
STK38LSerine/threonine kinase 38 likeRole in cell cycle, apoptosis
ARNTL2Aryl hydrocarbon receptor nuclear translocator-like protein 2*614517Regulates circadian rhythm
PPFIBP1Protein tyrosine phosphatase, receptor-type F interacting protein, binding protein 1*603141Interacts with proteins important for axon guidance and mammary gland development
MRPS35Mitochondrial ribosomal protein S35*611995Role in mitochondrial protein synthesis
KLHDC5Kelch domain containing protein 5Role in mitosis
PTHLHParathyroid hormone-like hormone*613382Role in chondrocyte proliferation, mutation causes brachydactyly type E
CCDC91Coiled-coil domain containing 91Required for ciliogenesis
FAR2Fatty acyl CoA reductase 2Putative role in wax ester biosynthesis and in other pathways such as ether lipid synthesis
ERGIC2Endoplasmic reticulum–Golgi intermediate compartment protein 2*612236Localized in nuclei of glandular epithelia, downregulated in prostate carcinoma
OVCH1Ovochymase 1Ovary-specific trypsin-like serine released during egg activation
TMTC1Transmembrane and tetratricopeptide repeat containing 1Role in protein adsorption and interfacial activity
Fig. 2

Genes located within the deletion 12p12.2p11.22 (9.17 Mb). (A) Array CGH profile of chromosome 12 using Agilent's 180K. (B) Zoomed in version of panel A. The difference in copy number is measured by the same units in both plots. Interstitial deletion on chromosome 12p12.2p11.22 (log2ratio < − 0.5). (C) Genes localized within the deleted region in our index patient according to Ensembl genome browser on human GRCh39/hg18.

Discussion

We report a patient with a de novo 9.2 Mb interstitial deletion on the short arm of chromosome 12 (12p12.2–p11.22) encompassing more than 40 reference genes. So far, ten other cases with interstitial deletions of the proximal part of chromosome 12 have been described (Bahring et al., 1997, Boilly-Dartigalongue et al., 1985, Glaser et al., 2003, Lu et al., 2009, Magenis et al., 1981, Malpuech G et al., 1975, Nagai et al., 1995, Orye and Craen, 1975, Soysal et al., 2011) and three patients with deletions extending more distally (Fryns et al., 1990, Lu et al., 2009, Tenconi et al., 1975). In the DECIPHER database (http://decipher.sanger.ac.uk) three additional cases with deletion 12p have been described (Table 1). When comparing the phenotype of the previously described cases with that of our patient, there is an overlap of clinical signs and symptoms such as psychomotor delay, microcephaly, facial dysmorphism including a flat nasal bridge and small ears, and ocular anomalies, particularly strabismus and bilateral optic nerve atrophy. These latter clinical signs and symptoms are unspecific and can be observed in association with various other chromosomal aberrations. We did not detect a correlation between the 12p deletion size or location and the clinical symptoms in the known cases including our index patient (Table 1, Fig. 3). Features reported previously in association with a 12p deletion but not present in our index patient were thoracic dystrophy, hair and skin changes, dental or skeletal anomalies, and borderline high blood pressure.
Fig. 3

Phenotype in relation to extent of interstitial 12p deletion. Positions of deletion are marked ▬. Within this region specific genes were associated with specific phenotypes.

Malignancies

A putative increased risk for development of malignancies exists in view of the oncogenes and tumor suppressor genes within the deleted region of 12p in our index patient (Table 2). These genes are: KRAS (Kirsten rat sarcoma viral oncogene homolog, OMIM*190070), which regulates homeostasis and tumorgenesis in the colon (Haigis et al., 2008) and has been identified to hold mutations in patients with Noonan syndrome (OMIM#609942). RECQL (OMIM*600537), encoding for DNA repair helicase, plays a role in chromosome fragility. Mutations in similar genes such as RECQL2/3 cause autosomal recessive Bloom Syndrome (OMIM#210900) and Werner Syndrome (OMIM#2777700). Moreover, CASC1 (cancer susceptibility candidate 1) polymorphisms have been described in several tumors, especially in lung cancer (Liu et al., 2003). Furthermore, there are a few in vitro data showing the importance of RASSF8 (OMIM#608231) for mitosis (Falvella et al., 2006, Lock et al., 2010, Sherwood et al., 2009). FGFR1OP2 (OMIM*608858) plays a role in the pathogenesis of myeloproliferative syndrome (Grand et al., 2004). STK38L is expressed in the process of squamous cell cancer development (Hummerich et al., 2006). ERGIC2 (OMIM*612236) encodes a ubiquitously expressed nuclear protein that is down-regulated in prostate carcinoma (Liu et al., 2003). In addition, the short arm of chromosome 12 has been found to rearrange in a wide spectrum of leukemic cells. In a subgroup of hematologic malignancies, multiple chromosomal breaks in the 12p12 to p13 region result in the formation of rearrangements including translocations, inversion, and deletions (Sato et al., 2001). So far no malignancies have been reported in patients with 12p deletions. However, the reported children are very young, and we propose a long-term follow-up and analysis of chromosome instability in all cases.

Microcephaly

Eight of the reported thirteen patients in Table 1 presented with microcephaly, a clinical finding also present in our patient. This finding may be explained through a deletion of genes with an important role in the cerebral development but the case of Magenis et al. (1981) also showed microcephaly and this does not overlap with the deleted region in our index patient (Fig. 3). In our patient the mentioned genes could be responsible for microcephaly. One such gene is sarcospan SSPN (OMIM*601599; Kras oncogene-associated gene), a gene that encodes a dystrophin–glycoprotein complex (DGC) member and plays a role in hypoxia induced glial cell death (Zhou et al., 2008). Further genes to consider are the serine/threonine kinase 38 like, important for cell cycle and apoptosis gene STK38L (Cornils et al., 2011, Vichalkovski et al., 2008) and the SOX5 gene (OMIM*604975, sex determining region Y-box 5). SOX genes are, in general, important for cell proliferation (Dugas et al., 2010), and SOX5 is, in particular, important for central nervous system development including oligodendrocyte differentiation and migration (Rosenfeld et al., 2010). Indeed, microcephaly is a recurrent feature in patients with 12p deletion but as mentioned above this can also be nonspecific. So far, none of the authors of other case reports specified the head circumference development. Postnatal microcephaly, as detected in our patient, could be secondary to apoptosis, as the patient did not display any evidence of a myelination disorder. It would be of interest to also differentiate between primary and secondary microcephaly in future reports.

Cardiovascular abnormalities

Four of the reported 13 patients display cardiovascular abnormalities not present in our patient, who only had a small PDA (persistent ductus arteriosus). There are two reference genes in the deleted region known to be associated with cardiovascular disorders: heterozygous mutations in ABCC9 (ATP-binding cassette, sub-family C member 9; OMIM*601439) cause dilated cardiomyopathy (Bienengraeber et al., 2004), and heterozygous deletions of PTHLH (OMIM+168470) can cause brachydactyly type E (OMIM#613382) and can be associated with arterial hypertension (Klopocki et al., 2010). Therefore, patients with deletion 12p need to be screened for abnormal blood pressure and pathological echocardiogram.

Microdeletion 12p

Analysis of G-banded metaphase chromosomes from the patient showed the presence of an interstitial deletion of the short arm of chromosome 12: karyotype 46XY, del(12)(p11.2p12.2). We performed array-CGH analysis to refine the extent of the deletion. This revealed a de novo interstitial deletion of 9.2 Mb in the 12p12.2-p11.22 region (chr12: 20,842,661-661-30,015,311, hg18), which contains more than 40 known genes (Table 2) and extends from position 20.48 Mb to 30.01 Mb (Fig. 2). The deletions of previously examined patients were determined merely by G-banding analysis. In the present study, we determined the extent of the deletion of our patient by array CGH to encompass about 9.2 Mb. It is a future task of clinical cytogenetics to more precisely characterize structural aberrations in order to define more clearly the cases with similar imbalances, which then can be studied with respect to phenotype and clinical variability. With our case report, we contribute to the understanding of the phenotype of patients with interstitial deletions of chromosome 12p. Knowledge of the pattern of this deletion-phenotype will help clinicians to diagnose this abnormality in their patients and to counsel the parents accordingly. Further descriptions may be able to contribute to the clarification. The following is the supplementary data related to this article.

Supplemental Fig. 1

Images of patient.
  28 in total

1.  Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.

Authors:  Effie K Grand; Francis H Grand; Andrew J Chase; Fiona M Ross; Martin M Corcoran; David G Oscier; Nicholas C P Cross
Journal:  Genes Chromosomes Cancer       Date:  2004-05       Impact factor: 5.006

2.  Deletion and point mutations of PTHLH cause brachydactyly type E.

Authors:  Eva Klopocki; Bianca P Hennig; Katarina Dathe; Randi Koll; Thomy de Ravel; Emiel Baten; Eveline Blom; Yves Gillerot; Johannes F W Weigel; Gabriele Krüger; Olaf Hiort; Petra Seemann; Stefan Mundlos
Journal:  Am J Hum Genet       Date:  2010-02-18       Impact factor: 11.025

3.  Deletion at 12p in a Japanese child with brachydactyly overlaps the assigned locus of brachydactyly with hypertension in a Turkish family.

Authors:  S Bähring; T Nagai; H R Toka; I Nitz; O Toka; A Aydin; A Mühl; T F Wienker; H Schuster; F C Luft
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

4.  Human NDR kinases control G(1)/S cell cycle transition by directly regulating p21 stability.

Authors:  Hauke Cornils; Reto S Kohler; Alexander Hergovich; Brian A Hemmings
Journal:  Mol Cell Biol       Date:  2011-01-24       Impact factor: 4.272

5.  The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways.

Authors:  F E Lock; N Underhill-Day; T Dunwell; D Matallanas; W Cooper; L Hesson; A Recino; A Ward; T Pavlova; E Zabarovsky; M M Grant; E R Maher; A D Chalmers; W Kolch; F Latif
Journal:  Oncogene       Date:  2010-05-31       Impact factor: 9.867

6.  Partial 12p deletion: a cause for a mental retardation, multiple congenital abnormality syndrome.

Authors:  N C Magnelli; E Therman
Journal:  J Med Genet       Date:  1975-03       Impact factor: 6.318

7.  Effects of PTX1 expression on growth and tumorigenicity of the prostate cancer cell line PC-3.

Authors:  Xianhong Liu; Ierachmiel Daskal; Simon C M Kwok
Journal:  DNA Cell Biol       Date:  2003-07       Impact factor: 3.311

8.  Identification of RASSF8 as a candidate lung tumor suppressor gene.

Authors:  F S Falvella; G Manenti; M Spinola; C Pignatiello; B Conti; U Pastorino; T A Dragani
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

9.  NDR kinase is activated by RASSF1A/MST1 in response to Fas receptor stimulation and promotes apoptosis.

Authors:  Anton Vichalkovski; Ekaterina Gresko; Hauke Cornils; Alexander Hergovich; Debora Schmitz; Brian A Hemmings
Journal:  Curr Biol       Date:  2008-12-09       Impact factor: 10.834

10.  Copy number variations associated with autism spectrum disorders contribute to a spectrum of neurodevelopmental disorders.

Authors:  Jill A Rosenfeld; Blake C Ballif; Beth S Torchia; Trilochan Sahoo; J Britt Ravnan; Roger Schultz; Allen Lamb; Bassem A Bejjani; Lisa G Shaffer
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

View more
  3 in total

1.  Application of high-resolution array comparative genomic hybridization in children with unknown syndromic microcephaly.

Authors:  Eirini Tsoutsou; Maria Tzetis; Krinio Giannikou; Maria Braoudaki; Anastasis Mitrakos; Stella Amenta; Nikoletta Selenti; Emmanouil Kanavakis; Dimitrios Zafeiriou; Sophia Kitsiou-Tzeli; Helena Fryssira
Journal:  Pediatr Res       Date:  2017-05-24       Impact factor: 3.756

2.  12p deletion spectrum syndrome: a new case report reinforces the evidence regarding the potential relationship to autism spectrum disorder and related developmental impairments.

Authors:  Marcio Leyser; Bruno Leonardo Dias; Ana Luiza Coelho; Marcio Vasconcelos; Osvaldo J M Nascimento
Journal:  Mol Cytogenet       Date:  2016-10-04       Impact factor: 2.009

3.  A 3.06-Mb interstitial deletion on 12p11.22-12.1 caused brachydactyly type E combined with pectus carinatum.

Authors:  Jia Huang; Hong-Yan Liu; Rong-Rong Wang; Hai Xiao; Dong Wu; Tao Li; Ying-Hai Jiang; Xue Zhang
Journal:  Chin Med J (Engl)       Date:  2019-07-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.